Dezube B J, Lederman M M, Chapman B, Georges D L, Dogon A L, Mudido P, Reis-Lishing J, Cheng S L, Silberman S L, Crumpacker C S
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
J Infect Dis. 1997 Sep;176(3):807-10. doi: 10.1086/517308.
Proinflammatory cytokines may be important in the pathogenesis of human immunodeficiency virus type 1 (HIV-1) disease. Tenidap decreases interleukin (IL)-6, IL-1, and tumor necrosis factor (TNF) production by peripheral blood mononuclear cells and decreases IL-6 plasma levels in rheumatoid arthritis patients. In this randomized double-blind study, 43 HIV-1-infected patients received tenidap (120 mg) or placebo daily for 6 weeks and then crossed over to the alternative therapy for an additional 6 weeks. Mean entry CD4 cell count was 140/microL. Analyses were performed on cytokines, acute-phase proteins, virus load, and CD4 cell counts. With the exception of small differences in plasma TNF levels, tenidap had no significant effect on these indices. Significant correlations of plasma IL-6 and TNF levels with HIV-1 RNA were noted. Six patients discontinued tenidap due to rash. The effects of tenidap in HIV-1 infection contrast to results in arthritis patients, in whom tenidap decreased plasma levels of IL-6 and acute-phase proteins.
促炎细胞因子可能在1型人类免疫缺陷病毒(HIV-1)疾病的发病机制中起重要作用。替硝唑可降低外周血单核细胞产生白细胞介素(IL)-6、IL-1和肿瘤坏死因子(TNF),并降低类风湿性关节炎患者的IL-6血浆水平。在这项随机双盲研究中,43名HIV-1感染患者每天接受替硝唑(120毫克)或安慰剂治疗,为期6周,然后交叉接受替代疗法,再持续6周。入组时CD4细胞计数的平均值为140/微升。对细胞因子、急性期蛋白、病毒载量和CD4细胞计数进行了分析。除血浆TNF水平存在微小差异外,替硝唑对这些指标无显著影响。观察到血浆IL-6和TNF水平与HIV-1 RNA之间存在显著相关性。6名患者因皮疹停用替硝唑。替硝唑在HIV-1感染中的作用与在关节炎患者中的结果形成对比,在关节炎患者中替硝唑可降低IL-6和急性期蛋白的血浆水平。